arrow
E

Elmar Stickeler

university hospital of rheinisch westfalische technische hochschule aachen
H指数:54
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025

AGO乳腺癌委员会关于乳腺癌手术治疗的建议:妇科肿瘤工作组(AGO)2025年更新

2025-09-170
PREAI
Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort study

乳腺癌新辅助治疗后低体积淋巴结受累患者的腋窝清扫术:多中心AXSANA队列研究

2025-09-010
PRE
Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – Results from the prospective AXSANA registry trial

新辅助化疗后腋窝超声的诊断性能——来自前瞻性AXSANA登记研究的结果

2025-07-050
PRE
Lost axillary markers after neoadjuvant chemotherapy in breast cancer patients - data from the prospective international AXSANA (EUBREAST 3) cohort study (NCT04373655)

新辅助化疗后乳腺癌症患者腋窝标记物丢失——来自前瞻性国际AXSANA(EUBREAST 3)队列研究(NCT04373655)的数据

2025-06-250
OA
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk

绝经前早期激素受体阳性、HER2阴性且复发风险增加的乳腺癌患者中,芳香化酶抑制剂、他莫昔芬和卵巢功能抑制的实际情况应用。

BREAST
IF7.9
2025-06-010
OAAI
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification

妊娠对乳腺癌免疫学的影响:免疫生物标志物和TIL量化

2025-05-140
OA
Radar reflectors for marking of target lymph nodes in initially node-positive patients receiving neoadjuvant chemotherapy for breast cancer-a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial
2025-02-200
PRE
Radar localization for targeted axillary dissection in breast cancer patients undergoing primary systemic treatment: a sub-analysis of the AXSANA study

乳腺癌患者在接受一线系统性治疗时,利用雷达定位进行靶向腋窝清扫的亚组分析:AXSANA研究的子分析

BREAST
IF7.9
2025-02-010
OAAI
Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry

palbociclib和ribociclib在HR阳性/HER2-negative转移性乳腺癌一线治疗中的头对头比较来自OPAL注册表的真实数据

2024-12-200
OA
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer
2024-11-010
OAAI
Association of RAD51 and efficacy outcomes in patients with HER2-negative breast cancer (BC) and homologous recombination deficiency (HRD): Post-hoc analysis of the GeparOla trial

RAD51与HER2阴性乳腺癌(BC)患者中同源重组缺陷(HRD)疗效结局的关联:GeparOla试验的事后分析

2024-09-010
PRE